A detailed history of Calton & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Calton & Associates, Inc. holds 3,987 shares of ABBV stock, worth $661,682. This represents 0.36% of its overall portfolio holdings.

Number of Shares
3,987
Previous 4,966 19.71%
Holding current value
$661,682
Previous $769,000 5.59%
% of portfolio
0.36%
Previous 0.31%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

SELL
$159.82 - $182.1 $156,463 - $178,275
-979 Reduced 19.71%
3,987 $726,000
Q4 2023

Feb 07, 2024

BUY
$137.6 - $154.97 $329,276 - $370,843
2,393 Added 93.0%
4,966 $769,000
Q3 2023

Nov 01, 2023

SELL
$133.59 - $154.65 $306,054 - $354,303
-2,291 Reduced 47.1%
2,573 $383,000
Q2 2023

Jul 24, 2023

SELL
$132.51 - $164.9 $9,143 - $11,378
-69 Reduced 1.4%
4,864 $655,000
Q1 2023

Apr 19, 2023

BUY
$144.61 - $166.54 $8,821 - $10,158
61 Added 1.25%
4,933 $786,000
Q4 2022

Jan 18, 2023

BUY
$138.31 - $165.87 $94,189 - $112,957
681 Added 16.25%
4,872 $0
Q3 2022

Oct 31, 2022

SELL
$134.21 - $153.93 $33,686 - $38,636
-251 Reduced 5.65%
4,191 $562,000
Q2 2022

Jul 12, 2022

SELL
$137.62 - $174.96 $155,785 - $198,054
-1,132 Reduced 20.31%
4,442 $680,000
Q1 2022

Apr 12, 2022

SELL
$131.98 - $163.75 $87,766 - $108,893
-665 Reduced 10.66%
5,574 $903,000
Q4 2021

Jan 13, 2022

SELL
$107.43 - $135.93 $277,061 - $350,563
-2,579 Reduced 29.25%
6,239 $844,000
Q3 2021

Nov 05, 2021

SELL
$106.4 - $120.78 $82,566 - $93,725
-776 Reduced 8.09%
8,818 $951,000
Q2 2021

Aug 11, 2021

SELL
$105.21 - $117.21 $99,318 - $110,646
-944 Reduced 8.96%
9,594 $1.08 Million
Q1 2021

May 03, 2021

SELL
$102.3 - $112.62 $920,495 - $1.01 Million
-8,998 Reduced 46.06%
10,538 $1.14 Million
Q4 2020

Jan 25, 2021

SELL
$80.49 - $108.67 $449,858 - $607,356
-5,589 Reduced 22.24%
19,536 $2.09 Million
Q3 2020

Oct 30, 2020

BUY
$85.91 - $100.83 $139,431 - $163,647
1,623 Added 6.91%
25,125 $2.2 Million
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $1 Million - $1.34 Million
13,688 Added 139.47%
23,502 $2.31 Million
Q1 2020

Apr 30, 2020

SELL
$64.5 - $97.79 $7,030 - $10,659
-109 Reduced 1.1%
9,814 $748,000
Q4 2019

Feb 03, 2020

BUY
$72.13 - $90.25 $216 - $270
3 Added 0.03%
9,923 $879,000
Q3 2019

Nov 07, 2019

BUY
$62.98 - $75.72 $39,866 - $47,930
633 Added 6.82%
9,920 $751,000
Q2 2019

Jul 09, 2019

BUY
$65.7 - $83.98 $17,739 - $22,674
270 Added 2.99%
9,287 $675,000
Q1 2019

Apr 25, 2019

SELL
$77.14 - $90.79 $77,525 - $91,243
-1,005 Reduced 10.03%
9,017 $727,000
Q4 2018

Feb 11, 2019

SELL
$77.85 - $96.01 $200,152 - $246,841
-2,571 Reduced 20.42%
10,022 $924,000
Q3 2018

Oct 24, 2018

BUY
$88.91 - $98.84 $41,965 - $46,652
472 Added 3.89%
12,593 $1.19 Million
Q2 2018

Aug 10, 2018

SELL
$89.78 - $106.23 $982,193 - $1.16 Million
-10,940 Reduced 47.44%
12,121 $1.14 Million
Q1 2018

Apr 17, 2018

BUY
$92.01 - $123.21 $358,010 - $479,410
3,891 Added 20.3%
23,061 $2.18 Million
Q4 2017

Feb 05, 2018

BUY
$89.56 - $98.21 $1.72 Million - $1.88 Million
19,170
19,170 $2.02 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $293B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Calton & Associates, Inc. Portfolio

Follow Calton & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Calton & Associates, Inc. with notifications on news.